1. Review the role of genomic testing in ER+ breast cancer.
2. Review data from TAILORx trial.
3. Review additional relevant ASCO presentations.
Gastrointestinal: Provide updates to evidence-based management options.
1. To review outcomesin recurrent uterine and ovarian cancer with both traditional chemotherapy and targeted agents.
2. To review most recent data on chemotherapy in rare gynecologic tumors.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation